Literature DB >> 15670804

Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures.

Alejandro J Roman1, Sharon B Schwartz, Tomas S Aleman, Artur V Cideciyan, John D Chico, Elizabeth A M Windsor, Leigh M Gardner, Gui-Shuang Ying, Elaine E Smilko, Maureen G Maguire, Samuel G Jacobson.   

Abstract

Pre-clinical trials of treatment in retinal degenerations have shown progress toward preventing loss or restoring function of rod photoreceptors. In anticipation of human clinical trials, we assessed two psychophysical methods of quantifying rod photoreceptor-mediated function as potential outcome measures. Modified automated perimeters were used to deliver focal or full-field light stimuli and dark-adapted thresholds were measured. Patients with retinal degeneration were studied in two experimental protocols. Experiment 1 (n = 35 patients) studied dark-adapted focal chromatic stimuli in central retinal locations along the horizontal meridian. Experiment 2 (n = 146 patients) studied dark-adapted responses to a full-field stimulus test (FST) using white and chromatic stimuli. Patients in both experimental groups had testing on two different visits to determine inter-visit variability. In Experiment 1, two subgroups of patients were identified: a group with a majority of test loci detected by rod photoreceptors and a group with only cone-mediated detection. Inter-visit variability (95% confidence interval) was +/-3.1 dB for normals, +/-3.0 dB for patients with rod-mediated function and +/-2.8 dB for patients with only cone-mediated function. In Experiment 2, the dynamic range of the FST using white stimuli was sufficient to quantify sensitivity in all patients studied, including those with severe retinal degenerations. Chromatic stimuli in the FST were detectable by 85% of patients and rod- or cone-mediation could be determined. Regional retinal sources of FST were explored by comparing FST and dark-adapted perimetry in the same patients; there was a strong correlation between FST level and the loci with highest sensitivity by perimetry. Inter-visit variability (95% confidence interval) in the patients was +/-3.9 dB compared to +/-3.5 dB in normals. Dark-adapted focal threshold measurements with an abbreviated protocol in retinal degeneration patients with stable fixation may be useful as an outcome measure for therapies that can affect rod vision. FST measurements were feasible and reproducible in a large spectrum of retinal degenerative diseases and will be most applicable as a psychophysical outcome measure for treatment trials of very severe disorders in which fixation is lost and there is need for a large dynamic range of stimulus intensity.

Entities:  

Mesh:

Year:  2005        PMID: 15670804     DOI: 10.1016/j.exer.2004.09.008

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  69 in total

1.  Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept.

Authors:  Astra Dinculescu; Jackie Estreicher; Juan C Zenteno; Tomas S Aleman; Sharon B Schwartz; Wei Chieh Huang; Alejandro J Roman; Alexander Sumaroka; Qiuhong Li; Wen-Tao Deng; Seok-Hong Min; Vince A Chiodo; Andy Neeley; Xuan Liu; Xinhua Shu; Margarita Matias-Florentino; Beatriz Buentello-Volante; Sanford L Boye; Artur V Cideciyan; William W Hauswirth; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Human CRB1-associated retinal degeneration: comparison with the rd8 Crb1-mutant mouse model.

Authors:  Tomas S Aleman; Artur V Cideciyan; Geoffrey K Aguirre; Wei Chieh Huang; Cristina L Mullins; Alejandro J Roman; Alexander Sumaroka; Melani B Olivares; Frank F Tsai; Sharon B Schwartz; Luk H Vandenberghe; Maria P Limberis; Edwin M Stone; Peter Bell; James M Wilson; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-29       Impact factor: 4.799

3.  Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Ramakrishna Ratnakaram; Elise Heon; Sharon B Schwartz; Alejandro J Roman; Marc C Peden; Tomas S Aleman; Sanford L Boye; Alexander Sumaroka; Thomas J Conlon; Roberto Calcedo; Ji-Jing Pang; Kirsten E Erger; Melani B Olivares; Cristina L Mullins; Malgorzata Swider; Shalesh Kaushal; William J Feuer; Alessandro Iannaccone; Gerald A Fishman; Edwin M Stone; Barry J Byrne; William W Hauswirth
Journal:  Arch Ophthalmol       Date:  2011-09-12

4.  Fundus-controlled two-color dark adaptometry with the Microperimeter MP1.

Authors:  Wadim Bowl; Knut Stieger; Birgit Lorenz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-24       Impact factor: 3.117

Review 5.  Statement of the DOG, the RG, and the BVA on the therapeutic use of voretigene neparvovec (Luxturna™) in ophthalmology. English version : January 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

6.  Retinal degeneration in children: dark adapted visual threshold and arteriolar diameter.

Authors:  Ronald M Hansen; Susan E Eklund; Ilan Y Benador; Julie A Mocko; James D Akula; Yao Liu; M Elena Martinez-Perez; Anne B Fulton
Journal:  Vision Res       Date:  2007-08-31       Impact factor: 1.886

7.  Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Igor V Peshenko; Alexander Sumaroka; Elena V Olshevskaya; Lihui Cao; Sharon B Schwartz; Alejandro J Roman; Melani B Olivares; Sam Sadigh; King-Wai Yau; Elise Heon; Edwin M Stone; Alexander M Dizhoor
Journal:  Hum Mol Genet       Date:  2012-10-03       Impact factor: 6.150

8.  Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce.

Authors:  Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk
Journal:  Transl Vis Sci Technol       Date:  2020-07-16       Impact factor: 3.283

9.  Retinal laminar architecture in human retinitis pigmentosa caused by Rhodopsin gene mutations.

Authors:  Tomas S Aleman; Artur V Cideciyan; Alexander Sumaroka; Elizabeth A M Windsor; Waldo Herrera; D Alan White; Shalesh Kaushal; Anjani Naidu; Alejandro J Roman; Sharon B Schwartz; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

10.  Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST).

Authors:  M Klein; D G Birch
Journal:  Doc Ophthalmol       Date:  2009-11-03       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.